NovaSight Inc

NovaSight Inc specializes in dynamic visual acuity testing systems. These devices are designed to evaluate and monitor visual function in clinical environments, helping healthcare providers assess patients' vision under different conditions. The primary focus is on diagnostic and treatment-related evaluations.

NovaSight Inc is headquartered in the United States. The company’s location is relevant for understanding its regulatory context, as it operates under U.S. medical device regulations.

NovaSight Inc’s devices fall under FDA Class II classification. This classification is determined based on the risk associated with the device—Class II devices generally pose moderate risk and require special controls to ensure safety and effectiveness, such as performance standards or post-market surveillance.

Yes, NovaSight Inc’s devices are included in the FDA’s Unique Device Identifier (UDI) database. Listing in the UDI system ensures traceability and transparency in the supply chain, allowing regulators, healthcare providers, and patients to identify and track specific medical devices.